✓
Open
4 Aug 2021
✓
Close
6 Aug 2021
3
Allotment
—
✓
Listing
Mon, Aug 16, 2021
Price Band
₹448 to ₹460
Issue Size
87,29,023 shares (agg. up to ₹402 Cr)
Lot Size
30 Shares
Listing Date
Mon, Aug 16, 2021
✦ AI Insight
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 14.54x |
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|
| Assets | 296.12 | 338.49 | 298.18 |
| Total Income | 430.70 | 331.34 | 311.53 |
| Profit After Tax | 15.57 | 16.21 | 63.82 |
| EBITDA | 54.52 | 34.00 | 37.74 |
| NET Worth | 199.12 | 209.66 | 193.59 |
| Reserves and Surplus | 192.71 | 203.25 | 187.17 |
| Total Borrowing | 31.32 | 27.43 | 29.91 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Glenmark Life Sciences Ltd. | Mainboard | ₹1,513.60 Cr | ₹720 | null | ₹748.50 | +3.96% | ₹1,133.30 (-2.59%) |
| Gland Pharma Ltd. | Mainboard | ₹6,479.55 Cr | ₹1500 | null | ₹1,819.55 | +21.30% | ₹2,449.00 (-3.29%) |
| Walpar Nutritions Ltd. | SME | ₹6.60 Cr | ₹55 | null | ₹57.00 | +3.64% | ₹34.50 (+0.00%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Purchase of equipment required for (i) capacity expansion of the existing facility at the Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant – II | 50.00 |
| 2 | Funding incremental working capital requirements of the Company | 47.56 |
| 3 | Repayment/prepayment of certain of the borrowings | 20.00 |
| 4 | General corporate purposes( | 34.60 |
About Windlas Biotech IPO
Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics. It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export. Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sac
Contact Details
Windlas Biotech Ltd. Address40/1, Mohabewala Industrial AreaDehradun, Uttarakhand, 248110+91 135 6608000grievance@windlasbiotech.comVisit Website